The funny part is folks payed 3x more for this company when it was at more of an intro hype phase, with 1/3 less revenue. It is a start-up like a biotech that you pay for the potential, rather than pure fundamentals. Here it is a year or two later, and with 3X more revenue its priced at 1/5 the high price.
It has solid technology with as broad an application base as I have ever seen. The "patent" may be worth the "market cap" alone. But this company has real scientists, and experienced management with fortune 100 manufacturing background, and a noted successful, passionate entrepreneur backing it, with significant retail experience. So even though its products are effective and highly valued by its market segment, it has the leadership to succeed in-spite of early stage financial challenges. Daymon John could finance this thing himself, if he wanted to, but then you and I would not be able to buy this $7 stock in 5 years for 8 cents today.
This is a diamond in the rough on multiple levels, and would be worth today's investment level even if it were just a "concept" being pitched in a VC board room.
I'm holding this to maturity.
I've let too many over my investing tenure get away...